amring-3d-icon-buildings

Recent Posts

• NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2025
• Nordic Group B.V. Through its Subsidiary Nordic Pharma, Inc. (U.S.), Announces LACRIFILL® Canalicular Gel Inclusion in New Dry Eye Workshop (DEWS) III Management and Therapy Report From The Tear Film and Ocular Surface Society (TFOS) in American Journal of Ophthalmology
• Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announces launch of authorized generic of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
• Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Presenting Patient Data and Patient Experience Study for LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
• Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces Details of LACRIFILL® Canalicular Gel Poster Presentation At SECO 2025